Document:

Exhibit 4.2

 

THE SECURITIES REPRESENTED HEREBY AND
THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE "U.S. SECURITIES ACT"). THE HOLDER HEREOF, BY ACQUIRING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION
THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 OR RULE 144A THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE
WITH ANY STATE SECURITIES LAWS OR (c) WITH THE PRIOR WRITTEN CONSENT OF THE CORPORATION, PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION
UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

Void after 5:00 p.m. (New York time) on
the [---] day of June 2022.

 

	Number of Warrants: 350,000	Warrant No. 5/2017-[A]

 

WARRANTS TO PURCHASE COMMON SHARES OF

Q BIOMED INC.

(organized under the laws of Nevada)

 

This is to certify that for value received
and in exchange for business development services that Q BioMed Inc. (the "Corporation") has received from William
S. Rosenstadt (the "Holder"),
the Holder shall have the right to purchase from the Corporation, at any time and from time to time up to from November [--], 2017
until 5:00 p.m. (New York time) on June [---], 2022 (the "Expiry
Time"), one fully paid and non-assessable Common Share (as hereinafter defined) for each Warrant (individually,
a "Warrant") represented hereby at a price of US$[---] per share (the "Exercise
Price"), upon and subject to the following terms and conditions:

 

1.            For the purpose of this Warrant, the term "Common
Shares" means common shares in the capital of the Corporation as constituted on the date hereof; provided that
in the event of a change, subdivision, re-division, reduction, combination or consolidation thereof or any other adjustment under
clause 7 hereof, or such successive changes, subdivisions, re-divisions, reductions, combinations, consolidations or other adjustments,
then subject to the adjustments, if any, having been made in accordance with the provisions of this Warrant Certificate, "Common
Shares" shall thereafter mean the shares, other securities or other property resulting from such change, subdivision,
re-division, reduction, combination or consolidation or other adjustment.

 

2.            All rights under any of the Warrants in respect of which the right of subscription and purchase therein not exercised shall
wholly cease and determine and such Warrants shall be wholly void and of no valid or binding effect after the Expiry Time. If B
(as defined in 3(3) below) is greater than the Exercise Price immediately prior to the Expiry Time, the Holder shall be deemed
to have exercised any remaining portion of this Warrant immediately prior to the Expiry Date in full pursuant to the cashless exercise
provision in 3(3), provided that the Holder has not notified the Company in writing prior to the Expiry Time that it is not taking
advantage of this provision.

 

     

     

    

Page 2

 

3.            The right to purchase Common Shares pursuant to the Warrants may only be exercised by the Holder before the Expiry Time
by:

 

		(1)	duly completing and executing a subscription substantially in the form attached hereto as Exhibit
A, in the manner therein indicated; and

 

		(2)	surrendering this Warrant Certificate and the duly completed and executed subscription form to
the Corporation at the principal office of the Corporation in the City of New York, together with payment of the purchase price
for the Common Shares subscribed for in the form of a wire transfer or a certified check payable to the Corporation in an amount
equal to the then applicable Exercise Price multiplied by the number of Common Shares subscribed for (“Aggregate Exercise
Price”); or

 

		(3)	subject to Section 7(c) herein, in the event the Holder desires to exercise the Warrant through
the cashless mechanism as set forth herein it shall, in lieu of making the cash payment otherwise contemplated to be made to the
Corporation upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net
Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):

 

		Net Number = (A x B) - (A x C)	 
	 	B	 
	 	For purposes of the
foregoing formula:	 

 

A= the total number of shares with
respect to which this Warrant is then being exercised.

 

B= the average closing bid price
of the Common Shares for the ten (10) Trading Days immediately preceding the date of the applicable Exercise Notice (“Average
Bid Price”).

 

C= the Exercise
Price then in effect for the applicable Warrant shares at the time of such exercise.

 

4.            Upon such delivery and payment as aforesaid, the Corporation shall cause to be issued to the Holder the number of Common
Shares to be issued and the Holder shall become a shareholder of the Corporation in respect of such Common Shares with effect from
the date of such delivery and payment and shall be entitled to delivery of a certificate or certificates evidencing such Common
Shares. The Corporation shall cause such certificate or certificates to be mailed to the Holder at the address or addresses specified
in such subscription form within five (5) business days of such delivery and payment as herein provided.

 

5.            The holding of a Warrant shall not constitute the Holder a shareholder of the Corporation nor entitle him to any right or
interest in respect thereof except as herein expressly provided.

 

     

     

    

Page 3

 

6.            The Corporation covenants and agrees that until the Expiry Time, while any of the Warrants shall be outstanding, it shall
reserve and there shall remain unissued out of its authorized capital a sufficient number of Common Shares to satisfy the right
of purchase herein provided, as such right of purchase may be adjusted pursuant to clauses 7 and 8 hereof. All Common Shares which
shall be issued upon the exercise of the right to purchase herein provided for, upon payment therefor of the amount at which such
Common Shares may at the time be purchased pursuant to the provisions hereof, shall be issued as fully paid and non-assessable
shares and the holders thereof shall not be liable to the Corporation or its creditors in respect thereof.

 

	7.	(a)	If and whenever at any time after the date hereof and prior to the Expiry Time the Corporation
shall (i) subdivide, re-divide or change its then outstanding Common Shares into a greater number of Common Shares, (ii) reduce,
combine or consolidate its then outstanding Common Shares into a lesser number of Common Shares, or (iii) issue Common Shares (or
securities exchangeable for or convertible into Common Shares) to the holders of all or substantially all of its then outstanding
Common Shares by way of a stock dividend or other distribution (any of such events herein called a "Common Share Reorganization"),
then the Exercise Price shall be adjusted effective immediately after the effective date of any such event in (i) or (ii) above
or the record date at which the holders of Common Shares are determined for the purpose of any such dividend or distribution in
(iii) above, as the case may be, by multiplying the Exercise Price in effect on such effective date or record date, as the case
may be, by a fraction, the numerator of which shall be the number of Common Shares outstanding on such effective date or record
date, as the case may be, before giving effect to such Common Share Reorganization and the denominator of which shall be the number
of Common Shares outstanding immediately after giving effect to such Common Share Reorganization including, in the case where securities
exchangeable for or convertible into Common Shares are distributed, the number of Common Shares that would be outstanding if such
securities were exchanged for or converted into Common Shares.

 

		(b)	If and whenever at any time after the date hereof and prior to the Expiry Time, the Corporation
shall distribute any class of shares or rights, options or warrants or other securities (other than those referred to in 7(a) above),
evidences of indebtedness or property (excluding cash dividends paid in the ordinary course) to holders of all or substantially
all of its then outstanding Common Shares, the Holder shall receive, in addition to the number of the Common Shares in respect
of which the right to purchase is then being exercised, the aggregate number of Common Shares or other securities or property that
the Holder would have been entitled to receive as a result of such event, as if, on the record date thereof, the Holder had been
the registered holder of the number of Common Shares to which the Holder was theretofore entitled upon the exercise of the rights
of the Holder hereunder.

 

		(c)	If and whenever at any time after the date hereof and prior to the Expiry Time there is a capital
reorganization of the Corporation or a reclassification or other change in the Common Shares (other than a Common Share Reorganization)
or a consolidation or merger or amalgamation of the Corporation with or into any other corporation or other entity (other than
a consolidation, merger or amalgamation which does not result in any reclassification of the outstanding Common Shares or a change
of the Common Shares into other securities), or a transfer of all or substantially all of the Corporation's undertaking and assets
to another corporation or other entity in which the holders of Common Shares are entitled to receive shares, other securities or
other property (any of such events being called a "Capital Reorganization"), the Holder, conditioned that he has
not exercised the right of subscription and purchase under this Warrant Certificate prior to the effective date of such Capital
Reorganization, shall be entitled to receive and shall accept, upon the exercise of such right, on such date or any time thereafter,
for the same aggregate consideration in lieu of the number of Common Shares to which he was theretofore entitled to subscribe for
and purchase less the aggregate Exercise Price per Warrant, the aggregate number of shares or other securities or property which
the Holder would have been entitled to receive as a result of such Capital Reorganization as if, on the effective date thereof,
he had been the registered holder of the number of Common Shares to which he was theretofore entitled to subscribe for and purchase.

 

     

     

    

Page 4

 

8.            On the occurrence of each and every such event set out in clause 7, the applicable provisions of this Warrant, including
the Exercise Price, shall, ipso facto, be deemed to be amended accordingly and the Corporation shall take all necessary action
so as to comply with such provisions as so amended.

 

9.            The Corporation shall not be required to deliver certificates for Common Shares while the share transfer books of the Corporation
are properly closed, having regard to the provisions of clause 7 hereof, prior to any meeting of shareholders or for the payment
of dividends or for any other purpose and in the event of the surrender of any Warrant in accordance with the provisions hereof
and the making of any subscription and payment for the Common Shares called for thereby during any such period delivery of certificates
for Common Shares may be postponed for not more than five (5) days after the date of the re-opening of said share transfer books.
Provided, however, that any such postponement of delivery of certificates shall be without prejudice to the right of the Holder
so surrendering the same and making payment during such period to receive after the share transfer books shall have been re-opened
such certificates for the Common Shares called for, as the same may be adjusted pursuant to clause 8 hereof as a result of the
completion of the event in respect of which the transfer books were closed.

 

10.          Subject
as hereinafter provided, all or any of the rights conferred upon the Holder by the terms hereof may be enforced by the Holder
by appropriate legal proceedings. No recourse under or upon any obligation, covenant or agreement contained herein shall be had
against any shareholder, director or officer of the Corporation either directly or through the Corporation, it being expressly
agreed and declared that the obligations under the Warrants are solely corporate obligations and that no personal liability whatever
shall attach to or be incurred by the shareholders, directors or officers of the Corporation or any of them in respect thereof,
any and all rights and claims against every such shareholder, officer or director being hereby expressly waived as a condition
of and as a consideration for the issue of the Warrants.

 

11.          The Holder may subscribe for and purchase any lesser number of Common Shares than the number of shares expressed in this
Warrant Certificate. In the case of any subscription for a lesser number of Common Shares than expressed in this Warrant Certificate,
the Holder hereof shall be entitled to receive at no cost to the Holder a new Warrant Certificate in respect of the balance of
Warrant not then exercised. Such new Warrant Certificate shall be mailed to the Holder by the Corporation, contemporaneously with
the mailing of the certificate or certificates representing the Common Shares issued pursuant to clause 4.

 

     

     

    

Page 5

 

12.          If this Warrant Certificate becomes stolen, lost, mutilated or destroyed, the Corporation shall, on such terms as it may
in its discretion acting reasonably impose, issue and sign and direct the Corporation's transfer agent to countersign a new Warrant
Certificate of like denomination, tenor and date as the Warrant Certificate so stolen, lost, mutilated or destroyed for delivery
to the Holder.

 

13.          The Corporation shall keep at its principal office (or its transfer agent in the City of New York): (a) a register of holders
in which shall be entered the names and addresses of the holders of the Warrants and of the number of Warrants held by them; and
(b) a register of transfers in which shall be entered the date and other particulars of each transfer of Warrants. The registers
hereinbefore referred to shall be open at all reasonable times for inspection by any Holder.

 

14.          Subject to compliance by the Holder with any applicable resale restrictions and any other applicable laws and regulatory
requirements, the Corporation acknowledges and agrees that the Warrants evidenced hereby may be assigned or transferred by the
Holder at the Holder's option. It is the sole responsibility of the Holder to ensure that all such restrictions, laws and regulatory
requirements have been observed. Upon any assignment or transfer, the Holder shall furnish the Corporation with this Warrant Certificate
and an Assignment Form in the form of Exhibit B attached hereto and such other documents and information regarding
the transferee as the Corporation may reasonably require to register these Warrants in the name of the transferee and, upon satisfaction
of such requirements, the Corporation shall execute and deliver a new Warrant Certificate in the name of the transferee named in
such Warrant Transfer Form for the number of unexercised Warrants and this certificate shall be promptly cancelled.

 

15.          The
transferee of a Warrant Certificate shall, after the transfer form attached to the Warrant Certificate or any other form of transfer
acceptable to the Corporation, acting reasonably, is duly completed and the Warrant Certificate is lodged with the Corporation
and upon compliance with all other conditions in that regard required by this Warrant, by the New York Stock Exchange or by law,
be entitled to have his name entered on the register of holders as the owner of the Warrants represented thereby free from all
equities or rights of set-off or counterclaim between the Corporation and the transferor or any previous holder of such Warrant,
save in respect of equities of which the Corporation or the transferee is required to take notice by statute or by order of a
court of competent jurisdiction.

 

16.          Warrant Certificates may, upon compliance with the reasonable requirements of the Corporation, be exchanged for Warrant
Certificates in any other denomination representing in the aggregate the same number of Warrants. The Corporation shall sign, all
Warrant Certificates necessary to carry out the exchanges contemplated herein, provided that:

 

		(1)	Warrant Certificates may be exchanged only at the principal office of the Corporation in the City
of New York; any Warrant Certificates tendered for exchange shall be surrendered to the Corporation and cancelled; and

 

		(2)	Except as otherwise herein provided, the Corporation may charge Holders requesting an exchange
a reasonable sum for each new Warrant Certificate issued; and payment of such charges and reimbursement of the Corporation for
any and all stamp taxes or governmental or other charges required to be paid shall be made by the party requesting such exchange
as a condition precedent to such exchange.

 

 

     

     

    

Page 6

 

17.          The
Corporation may deem and treat the registered holder of any Warrant Certificate as the absolute owner of the Warrants represented
thereby for all purposes, and the Corporation shall not be affected by any notice or knowledge to the contrary except where the
Corporation is required to take notice by statute or by order of a court of competent jurisdiction. A Holder shall be entitled
to the rights evidenced by such Warrant free from all equities or rights of set-off or counterclaim between the Corporation and
the original or any intermediate holder thereof and all persons may act accordingly and the receipt by any such Holder of the
Common Shares purchasable pursuant to such Warrant shall be a good discharge to the Corporation for the same and the Corporation
shall not be bound to inquire into the title of any such Holder except where the Corporation is required to take notice by statute
or by order of a court of competent jurisdiction.

 

18.          The
Holder acknowledges that appropriate legends, as follows, will be placed upon certificates representing any securities issued
on the exchange, assignment or exercise of the Warrants represented by this certificate until the hold period expires for the
Warrants so represented hereby.

 

LEGEND

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE “U.S. SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION
THAT SUCH SECURITIES MAY BE OFFERED, (A) TO THE CORPORATION, (B) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE 144 OR RULE 144A THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY STATE SECURITIES LAWS OR (C) WITH THE
PRIOR WRITTEN CONSENT OF THE CORPORATION, PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY
APPLICABLE STATE SECURITIES LAWS."

 

19.          This
Warrant shall be governed by the laws of the New York and the federal laws of the United States applicable herein.

 

20.          The Warrants represented by this certificate and the common shares issuable upon exercise hereof have not been registered
under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The Warrants represented
by this certificate may not be exercised by a U.S. person or person within the United States (or on behalf of any such person)
unless registered under the U.S. Securities Act or unless an exemption from such registration is available.

 

     

     

    

Page 7

 

IN WITNESS WHEREOF,
the Corporation has caused this Warrant Certificate to be signed by its duly authorized officer.

 

DATED this [-----]
day of May 2017.

 

	 	Q BIOMED INC.
	 	 	 
	 	By:	 
		 	Authorized Signing Officer

 

     

     

    

 

EXHIBIT A

 

EXERCISE NOTICE

 

TO BE EXECUTED BY THE REGISTERED HOLDER
TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

 

Q BIOMED INC.

 

The undersigned holder
hereby exercises the right to purchaseof the shares of Common Stock (“Warrant Shares”) of Q BioMed Inc.,
a Nevada corporation (the “Corporation”), evidenced by Warrant No. 5/2017-[A] (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

1.           Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:

 

__________________             a
“Cash Exercise” with respect to ______________ Warrant Shares; and/or

 

__________________             a
“Cashless Exercise” with respect to ___________ Warrant Shares.

 

In the event that the Holder has elected
a Cashless Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder hereby represents
and warrants that (i) this Exercise Notice was executed by the Holder at[a.m.][p.m.] on the date set forth below and (ii) if
applicable, the Bid Price as of such time of execution of this Exercise Notice was $       .

 

2.          Payment of Exercise Price. In the event that the Holder has elected a Cash Exercise with respect to some or all of
the Warrant Shares, the Holder shall pay the Aggregate Exercise Price in the sum of $to the Corporation in accordance with
the terms of the Warrant.

 

3.          Delivery of Warrant Shares and Net Number of shares of Common Stock. The Company shall deliver to Holder, or its
designee or agent as specified below, shares of Common Stock in respect of the exercise contemplated hereby. Delivery shall be
made to Holder, or for its benefit, to the following address:

 

___________________________

 

___________________________

 

___________________________

 

Date: ___________

 

     

     

    

Page 2

 

Name of Registered Holder

 

	By: 	    	 
	 	Name:	 
	 	Title:	 

 

	Account	 
	Number: 	 
	 	(if shares are delivered by electronic book entry transfer)

 

	Transaction Code
	Number: 	 
	 	(if shares are delivered by electronic book entry transfer)

 

     

     

    

Page 3

 

ACKNOWLEDGMENT

 

The Corporation hereby
acknowledges this Exercise Notice and hereby directs ______________ to issue the above indicated number of shares of Common Stock
in accordance with the Transfer Agent Instructions dated _________, 20__, from the Corporation and acknowledged and agreed to by
_______________.

 

	 	Q BIOMED INC.
	 	 	 
	 	By:	        
	 	Name:	 
	 	Title:	 

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

  

TO BE COMPLETED IF WARRANTS ARE TO BE
ASSIGNED:

  

	TO:	Q BioMed Inc.
	 	[address]

 

The undersigned holder of the within Warrant
certificate hereby sells, assigns and transfers to _____________________________________ [name of Transferee], _______________[number
of Warrants] of Q BioMed Inc. (the "Corporation") registered in the name of the undersigned on the records
of the Corporation represented by the attached Warrant certificate and irrevocably appoints _____________________________, the
attorney of the undersigned to transfer the said securities on the books or register with full power of substitution.

 

DATED this __________ day
of _____________________, 20_________.

 

	 	 	 
	Signature Guaranteed	 	Signature of Transferor

 

Certificate of Transferee

 

The undersigned certifies as follows (check one):

 

		A	[     ]	submits herewith evidence that the transfer of Warrants to the undersigned does not require
registration under the United States Securities Act of 19933, as amended, or any applicable securities laws, it being understood
that such evidence must be satisfactory in form and substance to the Corporation.

 

		B	[     ]	The undersigned hereby certifies that the undersigned is not in the United States, is not
acquiring the Warrants for the account or benefit of a person in the United States, was not offered the Warrants in the United
States and was not in the United States when it agreed to acquire the Warrants.

 

DATED this __________ day
of ________________, 20_____.

 

	 	 
	 	Signature of Transferee

 

     

     

    

Page 2

 

Instructions:

 

		a.	Signature of the Holder must be the signature of the person whose name appears on the face of the
Warrant Certificate.

 

		b.	If the Transfer Form is signed by a trustee, executor, administrator, curator, guardian, attorney,
officer of a corporation or any person acting in a fiduciary or representative capacity, the certificate must be accompanied by
evidence of authority to sign satisfactory to the Corporation.

 

		c.	Warrants shall only be transferable in accordance with applicable laws and are subject to the terms
and conditions contained in the certificate to which this Warrant Transfer Form is scheduled.

 

		d.	The signature of the Transferor on this Warrant Transfer Form must be guaranteed by a member of
a recognized Medallion Guarantee program.Exhibit 10.1

 

EXECUTIVE
SERVICES AGREEMENT

 

Executive
Services Agreement dated as of June 1, 2017 by and among Q BioMed Cayman SEZC (“Company”), and Denis Corin (the “Executive”).

 

W
I T N E S S E T H:

 

The
Company desire to engage the services of the Executive for purposes of general corporate management and development and more specifically
for those services set forth below (collectively, the “Executive Services”).

 

Executive
is desirous of performing the Executive Services on behalf of the Company and desires to be engaged and retained by the Company
for such purposes.

 

Accordingly,
in consideration of the recitals, promises and conditions in this Agreement, the Executive and the Company agree as follows:

 

1.       Executive
Services. The Company hereby retains the Executive to provide expertise in the areas of public company administration,
finance and corporate development to the Management and Board, and the Executive accepts such retention all on the terms and conditions
herein contained. Specific services are:

 

		(a)	to
                                         assist the company all executive, business development activities and business planning
                                         and direction
		(b)	to
                                         assist the Company in the implementation of financial controls and systems
		(c)	to
                                         assist Company in the negotiation of any business transactions
		(d)	to
                                         assist the Company in the preparation and filing of regulatory submissions
		(e)	to
                                         assist the Company in the area of financing and capital structure.

 

2.       Term.

 

(a)      Subject
to this Section 2(a), the initial term (the “Initial Term”) of this Agreement shall be for a two-year period commencing
on June 1st 2017.

 

3.       Compensation.
The Company shall pay and deliver to the Executive:

 

		●	Monthly
                                         retainer of $15,000
		●	Options
                                         (to acquire 100,000 shares of the common stock of the Company’s parent organization)
                                         which shall be granted pursuant to an Option Agreement attached hereto as Exhibit A
		●	Bonus
                                         Transaction Fees associated with any funding arranged or introduced to the company by
                                         mutual agreement between the parties and on a case by case basis, and which results in
                                         a financial transaction.

 

4.       Expenses:
The Company will reimburse Executive for all reasonable expenses incurred during performance of duties as Executive.

 

5.       Termination:
Either Company or Executive can terminate this Agreement by giving Ninety (90) days’ written notice. Company agrees
not to terminate (unless for cause) this Agreement during the ‘initial term’ unless there is clear evidence the Executive
is not performing duties in the best interests of Company. If the company terminates the agreement prior to the end of the initial
term, the Executive shall be entitled to any outstanding unpaid portion of reimbursable expenses, Transaction Fee (if the termination
is without cause), if any, and for the remainder of the unexpired portion of the applicable term (Initial Term or an agreed Extension
Period) of the Agreement (if the termination is without cause).

 

     

     

    

 

6.       Duties of the Company.

 

(a)      The
Company shall supply the Executive, on a regular and timely basis, with all approved data and information about the Company, its
management, its products and its operations, and the Company shall be responsible for advising the Executive of any facts which
would affect the accuracy of any prior data and information previously supplied to the Executive so that the Executive may take
corrective action.

 

(b)     The
Company shall promptly supply the Executive with: full and complete copies of all filings with all federal and state securities
agencies; full and complete copies of all stockholder stock reports and communications, whether or not prepared with the Executive’s
assistance; all data and information supplied to any analyst, broker-dealer, market maker or other member of the financial community;
and all product/services brochures, sales materials, etc.

 

(c)     The
Company shall contemporaneously notify the Executive if any information or data being supplied to the Consultant has not been
generally released or promulgated.

 

(d)     Other
specific obligations of the Company hereunder include the obligation to make all payments (including, but not limited to the stock
compensation) and/or deliveries of securities required hereunder (including, but not limited to the Common Shares) as due.

 

7.       Representatives and Indemnification by Company.

 

(a)      The
Company shall be deemed to make a continuing representation of the accuracy of any and all material facts, information and data
which it supplies to the Executive and the Company acknowledges its awareness that the Executive will rely on such continuing
representation in disseminating such information.

 

(b)     The
Executive, in the absence of notice in writing from the Company, will rely on the continuing accuracy of material, information
and data supplied by the Company.

 

(c)     The
Company hereby agree to indemnify the Executive against, and to hold the Executive harmless from, any claims, demands, suits,
loss, damages, etc. arising out of the Executive’s reliance upon the accuracy and continuing accuracy of such facts, material,
information and data, unless the Executive has been negligent in fulfilling its duties and obligations hereunder.

 

(d)     The
Company hereby agree to indemnify the Executive against, and to hold the Executive harmless from, any claims, demands, suits,
loss, damages, etc. arising out of the Executive’s reliance on the general availability of information supplied to the Executive
and the Executive’s ability to promulgate such information, unless the Executive has been negligent in fulfilling his duties
and obligations hereunder.

 

8.       Representatives and Indemnification by Executive.

 

The
Consultant agrees to provide the Executive Services hereunder in a manner consistent with the performance standards observed by
other professionals undertaking such functions.

 

9.       Confidentiality
and Other Provisions.

 

(a)      The
Executive shall not, except as authorized or required to perform the Executive Services, reveal or divulge to any person or Company
any of the trade secrets, secret or confidential operations, processes or dealings or any information concerning the organization,
business, finances, transactions or other affairs of the Company, which may come to its knowledge during the term of this Agreement
and shall keep in complete secrecy all confidential information entrusted to it and shall not use or attempt to use any such information
in any manner which may injure or cause loss, either directly or indirectly, to each Company’s business or may be likely
so to do. This restriction shall continue to apply after the termination of this Agreement without limit in point of time but
shall cease to apply to information or knowledge, which may come into the public domain. The Executive shall comply with such
directions, as the Company shall make to ensure the safeguarding or confidentiality of all such information.

 

    	 	2	 

     

    

 

(b)     During
the term of this Agreement, the Executive shall devote sufficient time, attention, and ability to the business of the Company,
and to any associated Company, as is reasonably necessary for the proper performance of the Executive Services pursuant to this
Agreement. During the term of this Agreement, the Executive shall:

 

		(i)	at
                                         all times perform the Executive Services to the best of its abilities and in the best
                                         interests of the Company; and

 

		(ii)	devote
                                         such of its time, labor and attention to the business of the Company as it, in its sole
                                         discretion, deems necessary for the proper performance of the Executive Services hereunder;
                                         and

 

10.     Miscellaneous.

 

(a)      Entire
Agreement; Amendments. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters.

 

(b)      Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile telephone number specified in this Section prior to 4:30 p.m. (Eastern Standard time) on a Business
Date, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile telephone number specified in this Agreement later than 4:30 p.m. (Eastern Standard time) on any date and earlier than
11:59 p.m. (Eastern Standard time) on such date, (iii) the Business Day following the date of mailing, if sent by nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall to the General Counsel of the Company at the Company’s registered address and if to
the Consultant: 

 

Denis
Corin

10
Market St, Suite 427

Camana
Bay, Grand Cayman, Cayman Islands

 

Tel.:
[345] 925 5363

Email:
dencorin@gmail.com

Attention:
Denis Corin

 

or
such other address as may be designated in writing hereafter, in the same manner, by such party.

 

(c)      Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an
amendment, by the Company and the Executive, or, in the case of a waiver, by the party against whom enforcement of any such waiver
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it
thereafter.

 

    	 	3	 

     

    

 

(d)      Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. All words used in this Agreement will be construed to be of such number and gender as
the circumstances require.

 

(e)      Successors
and Assigns. This Agreement is intended only for the benefit of, shall be binding upon and inure to the benefit of the parties
and their respective successors. Anything in the foregoing to the contrary notwithstanding, subject to compliance with applicable
securities laws, the Executive may assign and/or transfer all or a portion of the consideration payable by the Company hereunder.

 

(f)      Governing
Law. This Agreement shall be governed by, construed and enforced in accordance with the internal laws of the State of New
York without regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the non-exclusive
jurisdiction of the United States Federal District Court for the Southern District of New York for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, or that such suit, action or proceeding is improper under such court’s jurisdiction.

 

(g)     Severability.
In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect, the validity
and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby
and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

(h)     Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including the recovery of damages,
the Executive will be entitled to specific performance of the obligations of the Company hereunder. The Company and the Executive
agree that monetary damages would not be adequate compensation for any loss incurred by reason of any breach of its obligations
described in this Agreement and hereby agrees to waive in any action for specific performance of any such obligation the defense
that a remedy at law would be adequate.

 

[Remainder
of page intentionally left blank]

 

    	 	4	 

     

    

  

IN
WITNESS WHEREOF, the parties have hereunto set their hands and seals the day and year first above written.

 

	 	Q
    BioMed Inc.
	 	 	 
	 	By:	/s/
    William Rosenstadt
	 	 	William
    Rosenstadt
	 	 	General
    Counsel

 

	 	“Executive”
	 	 
	 	/s/
    Denis Corin
	 	Denis
    Corin

 

 

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]